AstraZeneca : Study Shows Heart Drug Brilinta Cuts Blood-Clot Formation
AstraZeneca Reports Positive Top-Line COPD Phase III Pinnacle Trial
First movers, including Bristol-Myers, and firms that can aggregate a portfolio of immuno-oncology therapies will be positioned well.
AstraZeneca Reaffirms its 2015 Earnings Guidance
Product durability, diversification, and cost synergies support strong earnings growth for this undervalued wide-moat firm.
UPDATE: FTSE 100 logs record closing high
LONDON MARKETS: FTSE 100 Logs Record Closing High
Asahi Kasei Pharma Selects Evotec as Its Partner for Ion Channel Drug Discovery
PEGASUS-TIMI 54 Study Shows That Long-Term Treatment with BRILINTA Reduced Thrombotic Cardiovascular Events in Patients with a History of Heart Attack
LONDON MARKETS: FTSE 100 Rises As Drug Makers, SABMiller Advance